TrialJournal for immunotherapy of cancer2019

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

Amy K Erbe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.